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a Abbreviations: ACh, acetylcholine; αBgtx, αBungarotoxin; Boc, t-butoxycarbonyl; Cbz, 
carbobenzyloxy; CNS, central nervous system; DCM, dichloromethane; DIAD, diisopropyl 
azodicarboxylate; DME, dimethoxyethane; Epi, epibatidine; nAChR, nicotinic acetylcholine receptor; 
SAR, structure activity relationship; TEA, triethylamine; THF, tetrahydrofurane.  
 
ABSTRACT. A series of unichiral analogues of 2R,2’S-2-(1’-methyl-2’-pyrrolidinyl)-7-hydroxy-1,4-
benzodioxane, a potent and selective α4β2-nAChR partial agonist, were designed by opening the 
dioxane ring and replacing hydroxyl carbon with nitrogen. The resulting 3-pyridyl ethers and meta-
hydroxyphenyl ethers have high α4β2 affinity and good subtype selectivity, which get lost if OH is 
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removed from phenyl or the position of pyridine nitrogen is changed. High α4β2 affinity and selectivity 
are also attained by meta hydroxylating the 3-pyridyl ether of (S)-N-methylprolinol, the corresponding 
phenyl ether and the phenyl ether of (S)-2-azetidinemethanol, known α4β2 agonists, although, on the 
basis of reported docking analyses, the interaction mode of the aryloxymethylene substructure of these 
compounds cannot be assimilated to that of benzodioxane. Indeed, the functional tests on the α4β2 and 
α3β4 subtypes well differentiate behaviors that the binding tests tend to make similar; in particular, they 
reveal that both the 3-hydroxyphenyl and the 5-hydroxy-3-pyridyl ether of N-methylprolinol are α4β2 
full agonists, but only the latter highly α4β2/α3β4  selective, while potent and selective partial α4β2 
agonism characterizes the hydroxybenzodioxane derivative and its two opened semi-rigid analogues. 
Introduction 
The widespread distribution in  the CNS and the key role in a number of CNS functions make α4β2 
neuronal nicotinic acetylcholine receptors (nAChRs) promising therapeutic targets in the treatment of 
CNS disorders such as neurodegenerative conditions, cognitive dysfunctions, pain, and nicotine 
dependence.1-6 Varenicline (Chart 1), an α4β2 agonist indicated for smoking cessation, has been 
approved for human use 7-10 and a number of selective α4β2 nAChR agonists have passed preclinical 
evaluations and the early stages of clinical trials before being abandoned. 6,11  
 
Chart 1. α4β2-nAChR partial agonists: Varenicline and 3,5-disubstituted pyridines  
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 More recently, selective α4β2 partial agonists have received considerable attention as novel 
antidepressants.12 Common features of their structures are 3-pyridyl bound to the alpha carbon of 
pyrrolidine or azetidine directly or through a flexible oxymethylene bridge, and the presence of a second 
substituent at the 5-position of pyridine nucleus, that confers selectivity for α4β2- over α3β4-nAChR 
subtype without prejudicing the high functional potency at the α4β2 receptor proper to the parent 
monosubstituted pyridines (Chart 1).13-18 Reducing the side effects due to activation or blockade of 
peripheral α3β4-nAChR is a central issue when developing centrally acting nicotinoids, and docking 
studies indicate that the substitution pattern at the pyridyl residue is determinant of very high 
α4β2/α3β4 binding selectivity because it directly influences the close interactions of pyridyl with non-
conserved residues on the β-side of the ligand-binding pocket and, in some cases, indirectly also the 
pose of the protonated amino group interacting with the conserved residues of the α-side.19-21 Coupled 
with such a subtype selectivity, potent partial agonism with low intrinsic activity seems to have higher 
therapeutic potential than full agonism or antagonism for reasons under debate. Indeed Varenicline is an 
α4β2-nAChR partial agonist and such a feature is shared by the majority of the α4β2-nAChR targeting 
ligands submitted to preclinical and clinical evaluation, for instance as antidepressants.12 
We have recently identified the 2R,2’S diastereomer of 2-(1’-methyl-2’-pyrrolidinyl)-1,4-
benzodioxane hydroxylated at the benzodioxane C(7) [(R,S)-3] as a new potent α4β2-nAChR partial 
agonist.22 The only one in a series of analogues with different 7-substituents to have  nanomolar binding 
affinity, (R,S)-3 resulted from a SAR study on 2-(1’-methyl-2’-pyrrolidinyl)-1,4-benzodioxane (2), an 
α4β2-nAChR ligand with moderate submicromolar affinity when S configured at the pyrrolidine 
stereocenter, in turn designed by rigidifying the phenoxymethylene portion of the known nicotinic 
agonist N-methylprolinol phenyl ether 1 23 in the 1,4-benzodioxane system (Chart 2).24,25  
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Chart 2. Design of conformationally restricted prolinol phenyl ethers 
 
The considerable enhancement of α4β2 affinity caused by the 7-OH substituent at the benzodioxane 
nucleus and the high α4β2 versus α3β4 functional selectivity of (R,S)-3 prompted us to study the effect 
of such a beneficial substitution also at the meta position of the conformationally free parent compound 
of 3, namely the prolinol phenyl ether 1, and of two semi-rigid analogues of 3, the prolinol 2-
methoxyphenyl ether 7 and the α-methylprolinol phenyl ether 8 (Chart 3). In addition to the phenyl 
ethers 1, 7 and 8 and their respective m-hydroxylated analogues 4, 9 and 10, we also considered the 
azetidinyl analogue 5 of 4 and the pyridines 6, 11, 12 and 13, which are isosteres  of 4, 7  and 8 (Chart 
3). 
Here, we report the synthesis of the compounds 4-13 and of the N-desmethyl analogues 4a-7a, 9a, 11a 
and 12a, in particular of the stereoisomers  with S configuration at the alicyclic amine stereocenter, their 
pharmacological evaluation as α4β2-nAChRs ligands and an SAR analysis based on the comparison 
between the affinity and activity profiles  of the conformationally uncostrained 3-pyridyl and 3-
hydroxyphenyl ethers 4, 5 and 6 on one side and of the hydroxybenzodioxane 3 and its semi-rigid 
opened analogues 7-13 on the other.  
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Chart 3. Target phenyl and 3-pyridyl ethers of prolinol and 2-azetidinemethanol.  
 
 
 
Chemistry 
Scheme 1 reports the synthesis of the S stereoisomers of the phenyl ethers 4, 7, and 9 and of the 
corresponding N-desmethyl analogues 4a, 7a, and 9a, which started from the Mitsunobu reaction 
between N-Cbz protected (S)-prolinol and 3-benzyloxyphenol, 2-methoxyphenol and 2-methoxy-5-
benzyloxyphenol to give, respectively, (S)-14, (S)-15 and (S)-16. The successive reduction of the Cbz 
protecting group with LiAlH4 converted (S)-14 into the N-methylprolinol 3-benzyloxyphenyl ether (S)-
17 and (S)-15 into the 2-methoxyphenyl ether (S)-7. Hydrogenolysis of (S)-17, (S)-14, (S)-15 and (S)-16 
provided (S)-4, (S)-4a, (S)-7a and (S)-9a respectively, while the 2-methoxy-5-hydroxyphenyl ether (S)-9 
was obtained from the intermediate  (S)-16 by treatment with hydrogen in the presence of formaldehyde. 
The azetidinyl analogues of 4 and 4a, namely (S)-5 and (S)-5a, were prepared from N-Boc protected (S)-
azetidinylmethanol,26,27 which was condensed with 3-benzyloxyphenol to give the m-benzyloxyphenyl 
ether (S)-18 and then debenzylated to the m-hydroxyphenyl ether (S)-19. Reduction with LiAlH4 
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converted (S)-19 into (S)-5, while Boc removal into (S)-5a. 
 
Scheme 1. Synthesis of compounds 4, 4a, 5, 5a, 7, 7a, 9 and 9a. 
 
Reagents and conditions: (a) 3-Benzyloxyphenol, PPh3, DIAD, THF, reflux, 18 h; (b) 2-Methoxyphenol, 
PPh3, DIAD, THF, 140 °C, 30 min, MW; (c) 2-Methoxy-5-benzyloxyphenol, PPh3, DIAD, THF, 120 
°C, 15 min, MW; (d) LiAlH4, THF, reflux, 2 h; (e) H2, Pd/C, MeOH, rt, 2 h; (f) H2, Pd/C, CH2O, 
MeOH, rt, 2 h; (g) 3-Benzyloxyphenol, PPh3, DIAD, THF, 140 °C, 30 min, MW; (h) 1.25 N HCl, 
MeOH, rt, 16 h. 
 
N-Cbz protected (S)-prolinol was the starting material also to synthesize the three pyridyl ethers (S)-6, 
(S)-11 and (S)-12 and the respective desmethyl analogues (S)-6a, (S)-11a and (S)-12a (Scheme 2). Its 
mesyl ester (S)-20 was reacted with the sodium salt of 3-benzyloxy-5-hydroxypyridine to give (S)-21, 
whose O- and N-deprotection by hydrogenolysis provided (S)-6a or, in the presence of formaldehyde, 
(S)-6. The reaction of (S)-20 with the potassium salt of 3-hydroxy-4-methoxypyridine gave the 
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intermediate 4-methoxy-3-pyridyl ether (S)-23, which was converted into (S)-12 and (S)-12a by 
hydrogenolysis in the presence or absence of formaldehyde respectively. The 2-methoxy-3-pyridyl ethers 
(S)-11 and (S)-11a were also synthesized from N-Cbz protected (S)-prolinol: Mitsunobu reaction with 2-
methoxy-3-hydroxypyridine yielded (S)-22, which was reduced to (S)-11 and (S)-11a by treatment with 
LiAlH4 or hydrogen respectively. 
 
Scheme 2. Synthesis of compounds 6, 6a, 11, 11a, 12 and 12a. 
OMs
N
Cbz
N
O
N
Cbz
N
O
N
Cbz
O
OBn
N
O
N
Cbz
O
(S)-6
(S)-6a
OH
N
Cbz
(S)-12
(S)-12a
(S)-11
(S)-11a
(S)-20
(S)-21
(S)-22
(S)-23
a
b c
d
e f
d
g
d
c
 
Reagents and conditions: (a) MsCl, TEA, DCM, rt, 2 h; (b) 3-Benzyloxy-5-hydroxypyridine, NaH, 
DMF, reflux, 4 h; (c) H2, Pd/C, CH2O, MeOH, rt, 2 h; (d) H2, Pd/C, MeOH, rt, 2 h; (e) 2-Metoxy-3-
hydroxypyridine, PPh3, DIAD, THF, 140 °C, 30 min, MW; (f) LiAlH4, THF, reflux, 2 h; (g) 3-Hydroxy-
4-methoxypyridinium trifluoroacetate, K2CO3, DMF, reflux, 24 h. 
The phenyl and pyridyl ethers of α-methylprolinol 8, 10 and 13 were prepared from N-Boc protected 
(S)-2-acetylpyrrolidine (Scheme 3). The reduction with LiAlH4 in THF at -10 °C afforded a near 
equimolar mixture of the diastereomeric alcohols (R,S)-24 and (S,S)-24, epimers at the exocyclic 
secondary carbon. The two diastereomers were separated by chromatography and the respective 
configurations were assigned on the basis of literature data.28 The (S,S)-24 diastereomer reacted with 
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phenol in the presence of DIAD/triphenylphosphine to give, in moderate yield, the phenyl ether (R,S)-
25. The reaction between (S,S)-24 and 3-benzyloxyphenol led to (R,S)-26, which was debenzylated to 
(R,S)-27. The Boc protecting group of both (R,S)-25 and (R,S)-27 was reduced to methyl with LiAlH4 to 
give (R,S)-8 and (R,S)-10 respectively. The R absolute configuration was assigned to the exocyclic 
stereocenter of 8 and 10 prepared from (S,S)-24 and, retrospectively, to the same carbon of the 
respective precursors 25, 26 and 27 with the aid of 1H NMR and conformational analysis. As reported in 
the Experimental section, the signal of the exocyclic methine is a quartet of doublets, resulting from 
coupling to the three methyl protons with a larger J value (∼6 Hz) and to the endocyclic methine proton 
with a smaller J value (∼3 Hz). Such a pattern indicates a relative sin disposition of the two methinic 
protons, which is favoured in the R,S diastereomer and virtually forbidden in the S,S diastereomer. This 
means that the two Mitsunobu reactions between (S,S)-24 and, respectively, phenol and 3-
benzyloxyphenol occurred with the same expected SN2 mechanism, which implies configuration 
inversion of the hydroxyl carbon. On the other hand, the (R,S)-24 diastereomer reacted with phenol in 
the presence of DIAD/triphenylphosphine to give, in very low yield, an equimolar (R,S)-25/(S,S)-25 
mixture, thus excluding a reaction mechanism based on the SN2 displacement by the phenol. The mixed 
(R,S)-25 and (S,S)-25 diastereomers were reduced to an equimolar mixture of (R,S)-8 and (S,S)-8, which 
was submitted to the binding tests as such, while postponing its resolution to the finding of high 
affinities for pure (R,S)-8 and/or for its mixture with (S,S)-8. 
An equimolar diastereomeric mixture of phenyl ethers, (R,S)-26 and (S,S)-26, resulted, in low yield, 
also from the Mitsunobu reaction between (R,S)-24 and 3-benzyloxyphenol. After hydrogenolytic 
debenzylation, the two phenols (R,S)-27 and (S,S)-27 were separated by chromatography and the 
purified (S,S)-27 was converted into (S,S)-10. Again, the configuration, S in this case, was assigned to 
the exocyclic stereocenter of 10 and, retrospectively, to the same carbon of the stereoisomer of its 
precursor 27 isolated by chromatography with the aid of 1H NMR and conformational analysis. Instead 
of the quartet of doublets observed in (R,S)-10 spectrum, the signal of the exocyclic methine was now a 
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quintet, resulting from coupling to the three methyl protons and to the endocyclic methine proton with 
the same relatively large J value (∼6 Hz). Such a multiplicity pattern is consistent with  a relative anti 
disposition of the two methinic protons, which is favoured in the S,S diastereomer and disfavoured in 
the R,S diastereomer. 
 
Scheme 3. Synthesis of compounds 8, 10 and 13.  
O
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(R,S)-27 X = OH
X
(R,S)-8
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N
(S,S)-28 (S,S)-13
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(R,S)/(S,S)-25
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O
N
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(S,S)-27  X = OH
X
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OH
N
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O
N N
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dd
e e c
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c
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g g
 
Reagents and conditions: (a) LiAlH4, THF, -10 °C, 1 h, chromatographic separation; (b) Phenol, PPh3, 
DIAD, THF, 150 °C, 30 min, MW; (c) LiAlH4, THF, reflux, 2 h; (d) 3-Benzyloxyphenol, PPh3, DIAD, 
THF, 150 °C, 30 min, MW; (e) H2, Pd/C, MeOH, rt, 2 h; (f) Chromatographic separation; (g) 3-
Hydroxypyridine, PPh3, DIAD, THF, reflux, 16 h. 
Lastly, to prepare (R,S)-13 and (S,S)-13, which are described as an unresolved diastereomeric 
mixture,29 the Boc protecting group of the secondary alcohols (R,S)-24 and (S,S)-24 was reduced to 
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methyl and the Mitsunobu reaction was carried out on the resulting N-methyl aminoalcohols (R,S)-28 
and (S,S)-28 by treatment with 3-hydroxypyridine in the presence of DIAD/triphenylphosphine. 
Differently from the hydroxyl carbon inversion and racemization observed in the etherification of (S,S)-
24 and (R,S)-24 respectively, (R,S)-13 and (S,S)-13 were formed with configuration retention from 
(R,S)-28 and (S,S)-28 respectively. Indeed, the signal of the exocyclic methinic proton in the 1H NMR 
spectrum of both (R,S)-28 and its derived pyridyl ether 13 is a quartet of doublets, as for (R,S)-8 and 
(R,S)-10, while the same signal is a quintet in the 1H NMR spectrum of both (S,S)-28 and its derived 
pyridyl ether 13, as for (S,S)-10. This can be explained by the formation of a bicyclic aziridinium ion 
intermediate: a double SN2, also called neighbouring group participation, in this case of the pyrrolidine 
basic nitrogen, would be responsible for the conservation of the configuration of the hydroxyl carbon. 
The isolation of 1-methyl-3-(3-pyridyloxy)piperidine as a by-product proves such a mechanism, which 
we had previously observed also in the chloride displacement from N-methyl-2-chloromethylpyrrolidine 
by acetone oximate anion.30 
 
Biology 
Binding studies. The synthesized compounds were tested in vitro on rat cerebral cortex or 
hippocampus membranes in order to evaluate their affinity at the α4β2 and α7 central nicotinic 
receptors labeled by [3H]-epibatidine ([3H]-Epi) and [125I]-αBungarotoxin ([125I]-αBgtx) and to evaluate 
their affinity on heterologously expressed human α3β4 receptors labeled with [3H]-Epi. Nicotine was 
included in the series for comparison. The results are listed in Table 1 together with those previously 
reported for (S)-1,23 (R,S)-2 25 and (R,S)-3.22  
 
Table 1. Nicotine and compounds 1-13: affinity for native α4β2 and α7 nAChR subtypes, in rat brain 
membranes, respectively labeled by [3H]-epibatidine and [125I]-αBungarotoxin, and heterologously 
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expressed human α3β4 nAChRs, labeled by [3H]-epibatidine. 
 
The Kd and Ki values were derived from three [
3H]-epibatidine and [125I]-αBungarotoxin saturation and 
three competition binding experiments using rat cortex (α4β2) and hippocampus (α7) membranes and 
the membrane of human α3β4 transfected cells as described in ref. 22 and 31. The curves were fitted 
using a nonlinear least squares analysis program and the F test. The numbers in brackets represent the 
%CV. The affinities of compounds 1, 2 and 3 are those previously reported in ref. 23, 25 and 22. 
On the basis of their α4β2 affinity, two groups of compounds can be distinguished. The first includes 
the compounds 3, 4, 5, 6, 9, 10, and 13, which have high α4β2 affinity (ranging from 1.1 to 27 nM), 
when S configured at the alicyclic amine stereocenter, and whose respective N-desmethyl analogues 
have considerably lower affinity except for 5a and 6a, which also have nanomolar α4β2 affinity. Their 
affinity for α7 is lower than their affinity for α4β2, (except for (S)-4a), with (S)-4, (S)-5a, (S)-6, (S)-6a 
 
α4β2 nAChR 
[3H]-Epi 
Ki (µM) 
α7 nAChR 
[125I]-αBgtx 
 Ki (µM) 
α3β4 nAChR 
[3H]-Epi 
Ki (µM)  
α4β2 nAChR 
[3H]-Epi 
Ki (µM) 
α7 nAChR 
[125I]-αBgtx 
 Ki (µM) 
α3β4 nAChR 
[3H]-Epi 
Ki (µM) 
Nicotine 0.004 (18) 0.234 (29) 0.261 (30) (R,S)-8 1.55 (29) 15.20 (21) 1.30 (32) 
(S)-1 0.042 - - (R,S)-8+(S,S)-8 4.59 (29) 8.90 (88) 1.40 (30) 
(R,S)-2 0.26 (32) 21 (44) 1.2 (28) (S)-9 0.0189 (33) 1.15 (61) 0.271 (37) 
(R,S)-3 0.012  (13) 0.427  (34) 0.310 (S)-9a 1.08 (37) nd 7.7 (25) 
(S)-4 0.0011 (29) 0.119 (25) 0.074 (100) (R,S)-10 0.0111 (18) 0.057 (32) 0.257 (38) 
(S)-4a 0.407 (26) 0.212 (42) 3.8 (119) (S,S)-10 0.192 (20) 0.743 (60) 0.752 (39) 
(S)-5 0.0085 (49) 0.029 (37) 0.102 (37) (S)-11 7.28 (29) nd 0.793 (25) 
(S)-5a 0.0071 (48) 1.20 (82) 0.040(42) (S)-11a 8.96 (37) nd 5.3 (28) 
(S)-6 0.0037 (29) 0.321 (27) 0.235 (57) (S)-12 0.255 (22) 9.40 (23) 2.10 (39) 
(S)-6a 0.0025 (19) 3.50 (60) 0.100 (46) (S)-12a 0.613 (16) 21.50 (26) 2.90 (40) 
(S)-7 9.4 (34) nd 0.749 (27) (R,S)-13 0.027 0.388 (21) 5.0 (32) 
(S)-7a 53.5 (38) nd 3.6 (30) (S,S)-13 0.877 6.100 (28) 5.6 (39) 
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and (S)-9 showing the greatest difference in affinity for α4β2 over α7. Their α3β4 affinity is also lower, 
with (S)-4, (S)-6, (S)-6a and (R,S)-13 showing the greatest difference in sensitivity for α4β2 over α3β4. 
The second group includes the compounds 7, 8, and 11 which all have very low α4β2 affinity, ranging 
from 1 to 10-50 µM Ki, regardless of N-methylation (7 and 11) or configuration (8), and  with no or 
even reversed α4β2/α3β4 selectivity. Compounds (S)-12 and (S)-12a fall between these two groups, 
having moderate submicromolar α4β2 affinity values, which are higher than those for α7 and α3β4 
subtypes. 
 
In vitro functional activity at nAChR. The affinity measurements indicate that the stereoisomers 
with S configuration at the alicyclic amine stereocenter of compounds 4, 5, 6, 9, 10, and 13 have high or 
very high affinity for α4β2 nAChRs and moderate or very low affinity for α3β4 and α7 nAChRs. These 
measurements give no indication of their possible functional activity and, consequently, neither of their 
actual functional selectivity between receptor subtypes. We have previously reported that (R,S)-3 shows 
26-fold lower α3β4 affinity (0.310 µM Ki) than that determined for the α4β2 subtype (0.012 µM Ki)  
against 214-fold lower α3β4 activity (EC5017.6 µM) than that measured for the α4β2 subtype (EC50 
0.082 µM). In order to determine the potency, efficacy and selectivity towards the α4β2 and α3β4 
subtypes we tested functionally compounds (S)-4, (S)-5, (S)-6, (S)-9 and (R,S)-13 and we compared the 
results with those of the compound (R,S)-3. 
Figure 1 shows electrophysiological effects of (S)-4, (S)-5, (S)-6, (S)-9, (R,S)-13  and (R,S)-3 on 
heterologously expressed human α4β2 and α3β4 nAChRs; table 2 shows all of the data normalized to 
those obtained upon superfusion of the same cell with 1 mM Ach. The electrophysiological study 
confirmed that (R,S)-3 (Fig. 1A) behaves as a partial agonist that is 57 times more potent on the α4β2 
subtype (EC50 0.3 ± 0.2 µM) than on the α3β4 subtype (17 ± 6 µM) and showed that the compound 
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(R,S)-13 (Fig. 1F) is a more potent and selective partial agonist than (R,S)-3, with an EC50 of 0.013 µM 
for the α4β2 subtype and no effect on the α3β4 subtype. 
We also determined that (S)-4 (Fig. 1B) behaves as a full agonist with a greater efficacy (166%) than 
ACh on the α4β2, but similar potency on the α4β2 (EC50 4.4 ± 0.6 µM) and α3β4 subtype (9 ± 2 µM). 
(S)-5 (Fig. 1C) also is a full agonist for the α4β2  and a partial agonist for the α3β4 subtype with an 
EC50 of 9.2 µM. Compound (S)-6 (Fig. 1D) is a very efficacious (661 ± 46% of 1 mM Ach) and 
selective α4β2 agonist with relatively low potency (73 ± 16 µM). Compound (S)-9 (Fig. 1E) has an 
inverted U shaped curve of activation for the α4β2 subtype (probably because it has a channel blocker 
activity at high concentration) and no effect on the α3β4 subtype.  
It is known that the heteromeric α4β2 and α3β4 can exist in two alternative stoichiometries: 2α/3β or, 
conversely, 3α/2β. In each receptor stoichiometry the two agonist orthosteric binding sites are at the two 
α/β interfaces and the presence of the fifth accessory subunit may confer differences to the receptor’s 
pharmacological properties.32 In the case of the α4β2 subtype the two stoichiometries differ greatly in 
pharmacology: ACh has an EC50 value of ≈ 1 µM 
32 and the agonist sazetidine is a full agonist for the 
(α4)2(β2)3 stoichiometry 
33 whereas towards the (α4)3(β2)2 stoichiometry ACh has an EC50 value of ≈ 
100 µM and sazetidine has a very low efficacy (6%). Analysis of the functional response of the α4β2 
subtype expressed in our cells shows that ACh has biphasic concentration-effect curve with the high 
affinity (0.4 µM) representing 33% and the low affinity (100 µM) 67% of the total ACh current (Table 3 
and Fig. 1H) and sazetidine (Fig. 1G) has a maximum response of 40% that of 1 mM ACh. These data 
indicate that in our cells both α4β2 stoichiometries are present and represent 1/3 [(α4)2(β2)3] and 2/3 
[(α4)3(β2)2] of the functional receptors. 
In the case of the α3β4 subtype, in agreement with the fact that the two stoichiometries have very 
similar EC50 values and potency for almost all nicotinic agonists,
14 we could not discriminate between 
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the expressed stoichiometries.          
   
 
Figure 1.  Agonist effects of (R,S)-3, (S)-4, (S)-5, (S)-6, (S)-9, (R,S)-13, sazetidine and ACh on 
transfected human α4β2 and α3β4 subtypes. Human α4β2  (), α3β4 (○) subtypes were transiently 
transfected into the GH4C1 rat anterior pituitary cell line and the activation responses are normalised to 
the maximal response to 1 mM ACh. 
 
Table 2. Effects of  (R,S)-3,  (S)-4 and (S)-5 on transfected human nicotinic receptor subtypes 
 
            α4β2 α3β4 
(R,S)-3 I / I MAX ACh (%) 29±4 (8)  28±3 (4) 
 EC50 (µM) 0.3±0.2 17±6 
 nH 1.1±0.7 0.9±0.2 
(S)-4 I / I MAX ACh  (%) 162±6 (4)  85±5 (7)  
 EC50 (µM) 4.4±0.6 9±2 
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 nH 0.91±0.08 1.3±0.4 
(S)-5 I / I MAX ACh (%) 131±1 (4)  57±1 (5)  
 EC50 (µM) - 9.2±0.5 
 nH - 1.5±0.2 
(S)-6 I / I MAX ACh (%) 661±46 (4) 15±2 (5)   
 EC50 (µM) 73±16 - 
 nH 0.66±0.03 - 
(S)-9 I / I MAX ACh (%) 17±5 (7) 7.0±0.5 (8) 
 EC50 (µM) - - 
 nH - - 
(R,S)-13 I / I MAX ACh (%) 39±1 (7) 7±4 (5) 
 EC50 (µM) 0.013±0.003 - 
 nH 0.7±0.1 - 
Sazetidine A I / I MAX ACh (%) 39±1 24±13 (4) 
 EC50 (µM) 0.00027±0.00006 - 
 nH 0.6±0.1 - 
Acetylcholine I / I MAX ACh (%) 33±8 (4) 100 (4) 
 67±8  
 EC50 (µM) 0.4 127±1 
 100  
 nH 0.6±0.5 1.5±0.3 
 1.6±0.9  
 
Dose–response curves were constructed by sequentially applying different concentrations of the 
indicated compounds, and normalizing the current amplitudes to the values obtained using 1 mM ACh 
on the same cell. For the quantitative estimates of agonist activity, the dose–response relationship was 
fitted when possible using  the equation: I = Imax [[C]nH/(EC50
nH + [C]nH)], where I is the peak current 
amplitude induced by the agonist at concentration [C], IMAX is the maximum response of the cell, nH the 
Hill coefficient, and EC50 the concentration at which a half maximum response is induced. Numbers in 
brackets represent the number of tested cells. 
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Discussion 
The introduction of OH into the 7-position of pyrrolidinyl-benzodioxane (R,S)-2 results in a 22-fold 
increase in α4β2 affinity: (R,S)-3 has 12 nM Ki against the 0.26 µM Ki of (R,S)-2.
22,25 Moreover, (R,S)-3  
is a potent α4β2 partial agonist, 200-fold selective over the ganglionic α3β4 subtype, as previously 
proved by a test of dopamine release from rat striatum (EC50 82 nM) 
22 and now confirmed on human 
α4β2 nicotinic receptors (EC50 0.3 µM). Consistently with such results, our previous docking analysis 
showed similar interactions of the protonated pyrrolidine ring and of the benzodioxane substructure of 
(R,S)-2 and (R,S)-3  with α4 and β2 aminoacid residues of the α4β2-nAChR binding pocket, but, only 
for (R,S)-3, additional H-bonds between the 7-hydroxyl and two serines, Ser(111) and Ser(115) of the β2 
subunit.22,25 These additional bonds would be responsible for the increased potency and the β2 
selectivity, while other substitutions than OH are found unproductive or deleterious apparently because 
only small substituents can be accepted at benzodioxane 7-position.22 
Compared to our pyrrolidinyl-benzodioxanes, nicotinoids with  a flexible oxymethylene bridge 
between the aromatic ring and the pyrrolidine residue, such as the 3-pyridyl ether of S-prolinol A-84543 
20,34 and its 5-alkinyl substituted analogues altinicline,19,20 (S)-29 19,20 and (S)-30 19 (Chart 4) similarly 
bind to the carbonyl group of Trp147, a conserved residue of the α4 subunit, through the pyrrolidine N+, 
but differently place the aromatic portion in the α4β2-nAChR binding pocket. In fact, though variously 
oriented, the pyridine ring of A-84543, altinicline, (S)-29 and (S)-30 always maintains π-π and strong 
hydrophobic interaction with Phe117, a non-conserved residue of the β2 subunit, with which the 
benzodioxane aromatic ring of (R,S)-2 and (R,S)-3 cannot interact due to the conformation of the 
oxymethine bridge, necessarily extended because part of the dioxane ring. On the other side, the pivotal 
role in the benzodioxane arrangement is played by the dioxane O(4) which replaces  pyridyl nitrogen in 
interacting with non-conserved Lys77(β2).22,25 Consistently with such a difference in the pose of the 
aromatic ring between pyridyl ethers and benzodioxanes, the pyridine ring is far from the mentioned β2 
Page 17 of 42
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 18
serine residues and tolerates elongated and bulky substituents at the 5-position,15-18 whereas the 
benzodioxane benzene approximates the serine residues and does not tolerate bulky substituents at the 7-
position, but only the small hydroxyl function eliciting beneficial H-bonds with those hydroxyl 
aminoacids.22 Although all these observations suggested that the unoccupied meta position of the 3-
pyridyl ethers and reasonably the meta position of the isosteric phenyl ethers is not assimilable to the 7-
position of pyrrolidine-benzodioxane, it was mandatory to investigate the effect of the meta-hydroxy 
substitution on the α4β2 affinity, activity and selectivity also of the phenyl and 3-pyridyl ethers of 
prolinol, which are the parent opened analogues of 2. 
 
Chart 4. The 3-pyridyl ether of (S)-N-methylprolinol (A-84543 ) and some its 5-alkinyl substituted 
derivatives. 
 
 
Indeed, these effects are different and absolutely not negligible. Compared to the unsubstituted phenyl 
ether of (S)-N-methylprolinol (S)-1, the meta-hydroxy analogue (S)-4 shows a 40-fold higher α4β2 
affinity (1.1 nM Ki) with a good selectivity over the α7 and α3β4 subtypes. Similar α4β2 affinity 
increase is produced also by the hydroxylation of the phenyl ether of 1-methyl-2-azetidinemethanol: (S)-
5 has a 12-fold higher affinity (8.5 nM Ki) than its non-hydroxylated analogue (101 nM Ki) 
23 and (S)-5a 
7-fold higher (7.1 nM versus 52 nM Ki 
23). Moreover, functional tests indicate that (S)-4 is a potent full 
α4β2 agonist (EC50 4.4 µM; 162% maximal efficacy relative to 1 mM ACh) and a partial α3β4 agonist 
N
O
A-84543
N
Me
N
O
N
Me
altinicline
N
O
N
Me
X
(S)-29  X = H
(S)-30  X = OH
Page 18 of 42
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19
(EC50 9 µM; 85% maximal efficacy relative to 1 mM ACh) showing, however, a functional α4β2 vs 
α3β4 selectivity sensibly lower than that found in the binding experiments. Again, the behavior of the 
azetidinyl analogue (S)-5 is near identical to that of (S)-5 as shown by the almost superimposable dose-
response curves (Fig. 1B and 1C). On the other hand, the meta hydroxylated (S)-prolinol 3-pyridyl ether 
(S)-6 maintains, without further improvements, the high α4β2 affinity and selectivity displayed by A-
84543 in binding assays, but interestingly it behaves as a full α4β2 agonist with a very high functional 
α4β2 vs α3β4 selectivity, much higher than that of A-84543 and of other unsubstituted 3-pyridyl ethers 
34 and resembling that of 2,5-diazabicylo[2.2.1]heptane 5-hydroxy-3-pyridyl substituted at the 2-
position.35     
In summary, as shown in Table 1, the five hydroxylated compounds (R,S)-3, (S)-4, (S)-5, (S)-5a and 
(S)-6 have very similar α4β2 nicotinic affinities and more or less pronounced α4β2 selectivity in 
binding experiments; thanks to hydroxylation, both the benzodioxane (R,S)-3 and the phenyl ethers (S)-
4, (S)-5 and (S)-5a are upgraded to the rank of pyridyl ethers A-84543 and (S)-6, selective α4β2 ligands 
with nanomolar affinity, although similar interaction modes, as previously explained, cannot be 
postulated for the aryl ethers and the benzodioxanes. It is reasonable that the 3-hydroxyphenyl 
derivatives can better interact than the unsubstituted phenyl ether (S)-1 and similarly to the 3-pyridyl 
ether A-84543, while the 5-hydroxy-3-pyridyl ether (S)-6 behaves as a wide number of 5-substituted 3-
pyridyl ethers of (S)-N-methylprolinol, 36 which generally maintain the nanomolar α4β2 affinity of A-
84543. Anyhow, the apparent similarity of the hydroxylated compounds in binding assays is unmasked 
by the functional tests, which give three quite different profiles for (R,S)-3, the pair of (S)-4 and (S)-5, 
and (S)-6: (a) the 7-hydroxybenzodioxane (R,S)-3 is confirmed to be a partial α4β2 and α3β4 agonist 
with high selectivity over the ganglionic subtype; (b) the 3-hydroxyphenyl ethers (S)-4 and (S)-5 are full 
α4β2 and partial α3β4 agonist with modest α4β2 selectivity, thus assimilable to A-84543; (c) the 5-
hydroxy-3-pyridyl ether (S)-6 is a full α4β2 agonist with practically no α3β4 activity. 
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Interestingly, also some pyrrolidine-furopyridines, designed by rigidifying the 3-pyridyloxymethylene 
portion of A-8453, show analogue behavior differences from the prolinol pyridyl ether which would 
mimick.37 In our series of compounds, the statement that the 7-hydroxybenzodioxane derivative has its 
own interaction mode, quite different from those of the 3-hydroxyphenyl ether and 5-hydroxy-3-pyridyl 
ether and highly advantaged by hydroxylation in proper position, is substantiated by the binding results 
obtained for compounds 7-13. These are phenyl and 3-pyridyl ethers of prolinol, formally obtained by 
opening the dioxane cycle of benzodioxane or pyridodioxane and thus maintaining some rigidity of the 
parent bicycle due to the residual α-methyl (compounds 8, 10 and 13) or ortho-methoxyl (compounds 7, 
9, 11 and 12). Compared to the unsubstituted benzodioxane (R,S)-2 (Ki 0.26 µM),  the 2-methoxyphenyl 
ether (S)-7, the phenyl ether of (S)-α-methylprolinol (R,S)-8 and the 2-methoxy-3-pyridyl ether (S)-11 
show much lower 1-10 micromolar α4β2 affinities and no α4β2 selectivity. This indicates that they lose 
the interaction abilities of benzodioxane system without acquiring those of flexible phenoxymethylene 
and 3-pyridyloxymethylene substructures. However, the phenyl m-hydroxylation again increases the 
α4β2 affinity: 500 times in the case of the 2-methoxy-5-hydroxyphenyl ether (S)-9 (cf. 18.9 nM Ki with 
9.4 µM Ki of (S)-7) and 140 times in the case of the 3-hydroxyphenyl ether of (S)-α-methylprolinol 
(R,S)-10 (cf. 11.1 nM Ki with 1.55 µM Ki of (R,S)-8). Also the α4β2 selectivity is similar to that of 
benzodioxanes (R,S)-2 and (R,S)-3 again. It is evident that the meta-hydroxyl plays a pivotal role and it 
can be presumed that such a substituent  drives the aryloxy fragment of (S)-9 and (R,S)-10 to interact 
similarly to the 7-hydroxybenzodioxane substructure of (R,S)-3. In the series of the three pyridyl ethers 
11-13, an analogous trend is observed to that of the phenyl ethers 7, 9 and 10, if the position of the 
pyridine nitrogen is considered instead of the meta-hydroxylation: (a) binding profile of (S)-11 identical 
to that of its carba-isostere (S)-7, namely very modest ~ 10 micromolar α4β2 affinity, even lower than 
α3β4 affinity; (b) moderate and high α4β2 affinity/selectivity of (S)-12 and (R,S)-13, respectively, 
which are both 3-pyridyl ethers and whose pyridine nitrogen is superimposable to the hydroxylated 
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carbon, respectively, of (S)-9 and (R,S)-10. The functional tests were performed on (S)-9 and (R,S)-13, 
selected among the opened benzodioxane analogues 7-13 because of their highest and most selective 
α4β2 affinity. As shown in figures 1E and 1F, the o-methoxylated hydroxyphenyl ether (S)-9 and the 
pyridyl ether of  α-methylated prolinol (R,S)-13 behave as partial α4β2 agonists like (R,S)-3 thus 
supporting the hypothesis of the similar interaction mode with α4β2 receptor suggested by the binding 
results. What is more, the deconstruction of 7-hydroxybenzodioxane to (S)-9 and, especially, to (R,S)-13 
increases the potency of the partial α4β2 agonism and suppresses α3β4 activity. 
For the compounds with only one stereocenter, namely 4-7, 9, 11 and 12, the N-desmethyl analogues 
were also considered. In the case of the only azetidinyl derivative, the N-desmetyl compound (S)-5a 
shows the same nanomolar α4β2 affinity as its N-methyl analogue (S)-5. On the other hand, all the N-
methyl-pyrrolidinyl derivatives, especially those OH-substituted at the benzene nucleus, display higher 
α4β2 affinity than the respective N-desmethyl analogues, as previously observed for the benzodioxane 
(R,S)-1 and (R,S)-3. The 5-hydroxy-3-pyridyl ether is an exception: it shows nanomolar α4β2 affinity 
whether methylated [(S)-6] or non-methylated [(S)-6a] and, interestingly, a very high α4β2 vs α7 
selectivity in the latter case. 
 
Conclusions 
The structures of  pyrrolidinyl benzodioxane 2 and of the prolinol phenyl  and 3-pyridyl ethers, 1 and 
A-84543, are superimposable and all display α4β2-nAChR affinity. The OH substituent at the 3-
position of phenyl in 1 and at the 7-position of benzodioxane in 2 enhances the α4β2 affinity to one and 
ten-nanomolar level respectively (compounds 4 and 3) and it is analogously beneficial when positioned 
in meta to the oxymethylene or oxymethine linker in a series of phenyl ethers we have designed as 
benzodioxane opened analogues (compounds 7-10). In a ligand-based approach, we have considered 
also the 5-OH substituted 3-pyridyl ether of N-methyl prolinol (compound 6), which maintains the 
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nanomolar α4β2 affinity of its non-hydroxylated analogue A-84543, and some 3-pyridyl ethers, the 
compounds 11-13, differently mimicking opened 2-pyrrolidinyl benzodioxane, which show moderate or 
high α4β2 affinity when the pyridine nitrogen can be superimposed to the benzodioxane hydroxylated 
C(7) as in compounds 12 and 13. Though internally coherent in appearance, the high α4β2 affinities of 
all our compounds hydroxylated  or with properly positioned pyridine nitrogen cannot be explained by a 
common interaction mode. On the basis of previously reported docking studies and of the present 
binding data, the pyrrolidinyl benzodioxanes 2 and 3 and their semi-rigid opened analogues 9, 10, 12 
and 13 would similarly interact with the α4β2-nAChR binding pocket and in a different manner from 
the flexible phenyloxmethyl and pyridyloxymethyl ethers 4-6, in particular by differently positioning the 
aromatic cycle. Such similarity and diversity are confirmed by the profiles of α4β2 agonism and 
selectivity over the ganglionic nicotinic subtype showed by the six compounds we have selected for 
functional tests, namely (a) the pyrrolidinyl hydroxybenzodioxane (R,S)-3 and its opened analogues (S)-
9 and (R,S)-13, which are all potent and selective α4β2 partial agonists with potency and α4β2/α3β4 
selectivity increasing in the order (R,S)-3<(S)-9<(R,S)-13, (b) the hydroxyphenyl ethers (S)-4 and (S)-5, 
potent and moderately selective α4β2 full agonists, and the hydroxypyridyl ether (S)-6, a higly 
efficacious and selective α4β2 full agonist. 
 
Experimental Section 
Chemistry. All chemicals and solvents were used as received from commercial sources or prepared as 
described in the literature. Flash chromatography purifications were performed using KP-Sil 32-63 µm 
60 Å cartridges. TLC analyses were carried out on alumina sheets precoated with silica gel 60 F254 and 
visualized with UV light; Rf values are given for guidance. 1H and 13C NMR spectra were recorded at 
300 and 75 MHz using an FT-NMR spectrometer. Chemical shifts are reported in ppm relative to 
residual solvent (CHCl3, MeOH or DMSO) as internal standard. Thermal analyses were performed on 2-
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5 mg samples in closed pans at 5°C/min using DSC 2010 TA INSTRUMENTS. Melting points 
correspond to the peak maximum. Optical rotations were determined in a 1 dm cell of 1 ml capacity. 
Elemental analyses (CHN) are within ± 0.40% of theoretical values. The results of elemental analyses 
indicated that the purity of all tested compounds was higher than 95%. In each described preparation, the 
moles of reagents are given for one mole of substrate. 
General Procedure for Synthesis of Compounds 13, 14-16, 18, 22, 25, and 26. The S isomers of 14, 
15, 16, and 22 were obtained by treatment of (S)-N-Cbz-2-hydroxymethylpyrrolidine with PPh3 (1.2 
mol), DIAD (1.2 mol) and equimolar 3-benzyloxyphenol (14), 2-methoxyphenol (15), 2-methoxy-5-
benzyloxyphenol (16) or 2-methoxy-3-hydroxypiridine (22). The S isomer of 18 was obtained by 
treatment of (S)-N-Boc-2-hydroxymethylazetidine with PPh3 (1.2 mol) , DIAD (1.2 mol) and equimolar 
3-benzyloxyphenol. The R,S isomer and the (R,S)/(S,S) diastereomeric mixture of 25 were prepared by 
combining PPh3 (2.2 mol), DIAD (2.2 mol) and equimolar phenol with (S,S)-24 and (R,S)-24 
respectively; the same reaction with 3-benzyloxyphenol in place of phenol gave the R,S isomer and the 
(R,S)/(S,S) diastereomeric mixture of 26 respectively. The compounds (R,S)-13 and (S,S)-13 were 
obtained from (R,S)-28 and (S,S)-28, respectively, by treatment with PPh3 (1.2 mol), DIAD (1.2 mol) 
and equimolar 3-hydroxypyridine. The reactions were carried out in THF at 66 °C for 16-18 hours (14 
and 13) or under microwave irradiation at 140 °C for 30 minutes (15 and 18), at 120 °C for 15 minutes 
(16) and at 150 °C for 30 minutes (25 and 26). The Mitsunobu condensations carried out on (R,S)-24 
gave (R,S)/(S,S) diastereomeric mixtures of 25 and 26  due to the racemization of the R stereocenter 
involved in the reaction. The diastereomeric mixture of (R,S)-25 and (S,S)-25 was not resolved, while 
that of (R,S)-26 and (S,S)-26 was resolved by chromatography on silica gel after debenzylation. 
(R,S)-N-Methyl-2-[1-(3-pyridyloxy)ethyl]pyrrolidine [(R,S)-13]. Obtained as a yellow oil in 15% yield 
after chromatography on silica gel (3% TEA in acetone): Rf = 0.42; [α]D
25 = -87.6 (c 1, MeOH); 1H 
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NMR (CDCl3) δ 8.27 (d, 1H, J = 2.0 Hz), 8.14 (dd, 1H, J = 4.1, 2.0 Hz), 7.20-7.12 (m, 2H), 4.42 (dq, 
1H, J = 6.3, 3.0 Hz), 3.06 (m, 1H), 2.41 (dt, 1H, J = 7.7, 3.0 Hz), 2.39 (s, 3H), 2.27-2.18 (m, 1H), 1.90-
1.66 (m, 4H), 1.26 (d, 3H, J = 6.3 Hz); 13C NMR (CDCl3) δ 16.3, 23.4, 26.5, 42.2, 58.1, 69.4, 74.9, 
122.9, 123.9, 139.9, 142.1, 154.6. 
(S,S)-N-Methyl-2-[1-(3-pyridyloxy)ethyl]pyrrolidine [(S,S)-13]. Obtained as a yellow oil in 18% yield 
after chromatography on silica gel (3% TEA in acetone): Rf = 0.39; [α]D
25 = +18.3 (c 1, MeOH); 1H 
NMR (CDCl3) δ 8.30 (d, 1H, J = 1.9 Hz), 8.17 (dd, 1H J = 3.9, 1.9 Hz), 7.23-7.15 (m, 2H), 4.41 (quint, 
1H, J = 6.1 Hz), 3.08 (m, 1H), 2.55 (m, 1H), 2.44 (s, 3H), 2.33-2.24 (m, 1H), 1.94-1.65 (m, 4H), 1.26 (d, 
3H, J = 6.1 Hz); 13C NMR (CDCl3) δ 15.9, 23.5, 27.5, 42.9, 58.4, 68.6, 77.7, 122.5, 124.0, 139.6, 142.1, 
154.4. 
(S)-N-Cbz-2-(3-benzyloxyphenoxymethyl)pyrrolidine [(S)-14 ]. Obtained as a light yellow oil in 81% 
yield after chromatography on silica gel (toluene/EtOAc 95:5): Rf = 0.32; [α]D
25 = -49.6 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.42-7.20 (m, 11H), 6.64-6. 48 (m, 3H), 5.15 (s, 2H), 5.04 (s, 2H), 4.28-4.19 (m, 
1H), 4.05-3.75 (m, 2H), 3.50-3.40 (m, 2H), 2.05-1.85 (m, 4H).  
(S)-N-Cbz-2-(2-methoxyphenoxymethyl)pyrrolidine [(S)-15]. Obtained as a light yellow oil in 52% 
yield after chromatography on silica gel (toluene/EtOAc 8:2): Rf = 0.56; [α]D
25 = -54.1 (c 1, CHCl3); 
1H 
NMR (CDCl3) δ 7.43-7.22 (m, 5H), 7.10-6.64 (m, 4H), 5.16 (s, 2H), 4.38-4.24 (m, 2H), 4.10-3.98 (m, 
1H), 3.82 (s, 3H), 3.58-3.38 (m, 2H), 2.21-1.83 (m, 4H).  
(S)-N-Cbz-2-(2-methoxy-5-benzyloxyphenoxymethyl)pyrrolidine [(S)-16]. Obtained as a light yellow 
oil in 51% yield after chromatography on silica gel (toluene/EtOAc 8:2): Rf = 0.47; [α]D
25 = -33.1 (c 1, 
CHCl3); 
1H NMR (CDCl3): δ 7.45-7.21 (m, 10H), 6.81 (m, 1H), 6.60 (m, 1H), 6.45 (m, 1H), 5.12 (s, 
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2H), 5.02 (m, 2H), 4.28-4.08 (m, 3H), 3.81 (s, 3H), 3.58-3.40 (m, 2H), 2.10-1.85 (m, 4H). 
(S)-N-Boc-2-(3-benzyloxyphenoxymethyl)azetidine [(S)-18]. Obtained as a light yellow oil in 74% 
yield after chromatography on silica gel (cyclohexane/EtOAc 8:2): Rf = 0.61; [α]D
25 = -73.3 (c 0.9, 
CHCl3); 
1H NMR (CDCl3) δ 7.25-7.45 (m, 5H), 7.18 (m, 1H), 6.50-6.62 (m, 3H), 5.04 (s, 2H), 4.52-
4.45 (m, 1H), 4.23 (m, 1H), 4.05 (dd, 1H, J = 10.2 and 2.7 Hz,), 3.99-3.86 (m, 2H), 2.39-2.17 (m, 2H), 
1.26 (s, 9H). 
(S)-N-Cbz-2-(2-methoxy-3-pyridyloxymethyl)pyrrolidine [(S)-22]. Obtained as a light yellow oil in 
48% yield after chromatography on silica gel (toluene/EtOAc 9:1): Rf = 0.22; [α]D
25 = -41.6 (c 1, 
CHCl3); 
1H NMR (CDCl3) δ 7.70 (m, 1H), 7.36-7.26 (m, 5H), 6.80-6.91 (m, 1,5H), 6.57 (m, 0.5H), 5.15 
(s, 2H), 4.28-4.04 (m, 2H), 3.98 (s, 3H), 3.84-3.72 (m, 1H), 3.50-3.31 (m, 2H), 2.20-1.80 (m, 4H). 
(R,S)- and (S,S)-N-Boc-2-(1-phenoxyethyl)pyrrolidine [(R,S)-25 + (S,S)-25]. Obtained as a yellow oil 
in 10% yield after chromatography on silica gel (tolune/EtOAc 9:1) in 1:1 distereomeric ratio, as proved 
by the presence of two equally intense singlets, integrating for 9 H, due to the tert-butyl and two equally 
intense doublets, integrating for 3 H, due to the methyl: Rf = 0.47; 
1H NMR (CDCl3) δ 7.29-7.07 (m, 
6H), 6.89 (m, 4H), 5.03-4.70 (m, 2H), 4.21-4.12 (m, 1H), 3.86-3.79 (m, 1H), 3.47-3.16 (m, 4H), 2.32-
1.79 (m, 8H), 1.56 (s, 9H), 1.42 (s, 9H), 1.25 (d, 3H, J = 6.3 Hz), 1.21 (d, 3H, J = 6.3 Hz). 
(R,S)-N-Boc-2-(1-phenoxyethyl)pyrrolidine [(R,S)-25]. Obtained as a yellow oil in 46% yield after 
chromatography on silica gel (tolune/EtOAc 9:1): Rf = 0.47; [α]D
25 = -120.7 (c 1, CH3OH); 
1H NMR 
(CDCl3) δ 7.29-7.07 (m, 3H), 6.89 (m, 2H), 5.03 (m, 0.6 H), 4.70 (m, 0.4 H), 3.86-3.79 (m, 1H), 3.47-
3.16 (m, 2H), 2.23 2,15- (m, 1H), 2.02-1.79 (m, 3H), 1.42 (s, 9H), 1.25 (d, J = 6.3 Hz, 3H). 
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(R,S)- and (S,S)-N-Boc-2-[1-(3-benzyloxyphenoxy)ethyl)]pyrrolidine [(R,S)-26 + (S,S)-26]. Obtained 
as a yellow oil in 7% yield after two chromatographies on silica gel, first with 9:1 cyclohexane /EtOAc 
and then with 9:1 toluene/acetone, in 1:1 diastereomeric ratio as proved by the two equally intense 
singlets, integrating for  9 H, due to tert-butyl and the two equally intense doublets, integrating for 3 H, 
due to the methyl: 1H NMR (CDCl3) δ 7.44-7.29 (m, 10H), 7.13 (m, 2H), 6.52 (m, 6H), 5.04 (s, 2H), 
5.02 (s, 2H), 4.25-4.12 (m, 2H), 3.79-3.86 (m, 2H), 3.47-3.16 (m, 4H), 2.06-1.70 (m, 8H), 1.56 (s, 9H), 
1.44 (s, 9H), 1.24 (d, J=6.3 Hz, 3H), 1.20 (d, J=6.3 Hz, 3H). 
(R,S)-N-Boc-2-[1-(3-benzyloxyphenoxy)ethyl]pyrrolidine [(R,S)-26]. Obtained as an oil in 44% yield 
after chromatography on silica gel (cyclohexane/EtOAc 9:1): Rf = 0.43; [α]D
25 = -75.1 (c 0.5, CH3OH); 
1H NMR (CDCl3) δ 7.44-7.29 (m, 5H), 7.13 (m, 1H) 6.52 (m, 3H), 5.02 (s, 2H), 4.09-3.86 (m, 2H), 
3.42-3.08 (m, 2H), 2.07-1.65 (m, 4H), 1.44 (s, 9H), 1.24 (d, J=6.3 Hz, 3H). 
(S)-N-Cbz-2-mesyloxymethylpyrrolidine [(S)-20]. Obtained as a solid in 90% yield by treatment 
with mesyl chloride (1.1 mol) and TEA (1.1 mol) in DCM at  room temperature for 2 h, 1 N HCl/DCM 
extraction and chromatography on silica gel (cyclohexane/EtOAc 7:3): Rf = 0.30; mp 43.7 °C; [α]D
25 = -
51.0 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.38-7.30 (m, 5H), 5.13 (s, 2H), 4.32-4.05 (m, 3 H), 3.48-3.43 
(m, 2 H), 2.95-2.83 (m, 3 H), 2.17-1.85(m, 4 H). 
(S)-N-Cbz-2-(5-benzyloxy-3-pyridyloxymethyl)pyrrolidine [(S)-21]. Obtained as a light yellow oil 
in 42% yield by treatment of (S)-20 with 3-benzyloxy-5-hydroxypyridine (1 mol) and NaH (1 mol) in 
boiling DMF for 4 h and chromatography on silica gel (DCM/acetone 95:5): Rf = 0.42 [α]D
25 = -50.1 (c 
0.5, CHCl3); 
1H NMR (CDCl3) δ 8.05-7.91 (m, 2H), 7.26-7.41 (m, 10H), 6.93 (m, 0.7H), 6,78 (m, 
0.3H), 5.03-5.22 (m, 4H), 4.22 (m, 2H), 4.19 (m, 0.7H), 3.82 (m, 0.3H), 3.56 (m, 2H), 2.17-1.88 (m, 
4H). 
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(S)-N-Cbz-2-(4-methoxy-3-pyridyloxymethyl)pyrrolidine [(S)-23]. Obtained as a light yellow oil in 
51% yield by treatment of (S)-20 with the trifluoroacetate salt of 3-hydroxy-4-methoxypyridine (0.8 
mol) and K2CO3 (1.6 mol) in boiling DME overnight and chromatography on silica gel (DCM/acetone 
9:1): Rf = 0.34; [α]D
25 = -31.4 (c 1, CHCl3); 
1H NMR (CDCl3) δ 8.21-8.08 (m, 2H), 7.33-7.26 (m, 5H) 
6.77 (d, J = 5.2 Hz, 1H), 5.14 (m, 2H), 4.26-4.04 (m, 3H), 3.87 (s, 3H), 3.48 (m, 2H), 2.17-1.85 (m, 4H). 
(R,S)-N-Boc-2-(1-hydroxyethyl)pyrrolidine [(R,S)-24].
28
 Obtained as an oil in 42% yield by 
treatment of (S)-N-Boc-2-acetylpyrrolidine with LiAlH4 (2 mol) in THF at -10 °C for 1h and successive 
chromatography on silica gel (toluene/acetone 7:3): Rf = 0.57; [α]D
25 = -74.2 (c 1, CH3OH); 
1H NMR 
(CDCl3) δ 3.96–3.84 (m, 2H), 3.54 (m, 1H), 3.24 (m, 1H), 3.13 (bs, 1H, exchange with D2O), 2.17-1.95 
(m, 1H), 1.87-1.79 (m, 1H), 1.77-1.68 (m, 2H), 1.47 (s, 9H), 1.08 (d, 3H, J = 6.3 Hz); 13C NMR 
(CDCl3) δ 17.9, 24.3, 27.9, 28.7, 48.3, 63.6, 69.9, 80.3, 156.6. 
(S,S)-N-Boc-2-(1-hydroxyethyl)pyrrolidine [(S,S)-24]. Obtained as a white solid in 51% yield as 
described for (R,S)-24: Rf = 0.53, m.p. = 62.3 °C; [α]D
25 = -54.8 (c 1, CH3OH); 
1H NMR (CDCl3) δ 4.31 
(bs, 1H, exchange with D2O), 3.75-3.61 (m, 2H), 3.52-3.44 (m, 1H), 3.24 (m, 1H), 1.99–1.87 (m, 1H), 
1.84-1.70 (m, 2H), 1.68-1.54 (m, 1H), 1.47 (s, 9H), 1.13 (d, 3H, J = 6.0 Hz); 13C NMR (CDCl3) δ 21.1, 
24.2, 28.7, 29.1, 47.6, 64.5, 72.4, 80.7, 158.1. 
General Procedure for Synthesis of Compounds 4, 4a, 6a, 7a, 9a, 11a, 12a, 19, and 27. The S 
isomers of 4, 4a, 6a, 7a, 9a, 11a, 12a, and 19  and the R,S isomer of 27 were obtained by hydrogenolysis 
(H2 1 atm, Pd/C) of (S)-17, (S)-14, (S)-21, (S)-16, (S)-15, (S)-22, (S)-23, (S)-18, and (R,S)-26, 
respectively, in MeOH at room temperature for 2 hours. Under the same conditions, the S,S isomer of 27 
was obtained by hydrogenation of the (R,S)/(S,S) diastereomeric mixture of 26 and successive 
chromatographic separation.  
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(S)-N-Methyl-2-(3-hydroxyphenoxymethyl)pyrrolidine [(S)-4]. Obtained as a yellow oil in 84% yield: 
[α]D
25 = +15.0 (c 0.5, CHCl3); 
1H NMR (CDCl3) δ 7.05 (t, J = 8.4 Hz, 1H), 6.41 (m, 3H), 5.30 (s, 1H, 
exchange with D2O), 3.99-3.82 (m, 2H), 3.21-3.17 (m, 1H), 2.82-2.77 (m, 1H), 2.59 (s, 3H) 2.41-2.32 
(m, 1H), 2.18-1.56 (m, 4H); 13C-NMR (CDCl3) δ 23.0, 28.6, 42.5, 58.1, 64.9, 70.6, 103.2, 105.6, 109.2, 
130.1, 158.3, 160.0. 
(S)-2-(3-Hydroxyphenoxymethyl)pyrrolidine [(S)-4a]. Obtained as a beige solid in 88% yield: m.p. = 
121.8 °C; [α]D
25 = -5.86 (c 0.5, CHCl3); 
1H NMR (CDCl3) δ 7.10 (t, 1H, J = 8.3 Hz), 6.72 (m, 1H), 6.46 
(dd, 1H, J = 8.3, 2.2 Hz), 6.33 (d, 1H, J = 8.3, 2.2 Hz), 5.42 (bs, 2H, exchange with D2O), 4.13-3.89 (m, 
1H), 3.79-3.61 (m, 2H) 3.02 (m, 2H) 2.12-1.96 (m, 1H), 1.93-1.79 (m, 2H), 1.61-1.55 (m, 1H); 13C-
NMR (CDCl3) δ 25.6, 27.9, 45.9, 56.8, 70.5, 103.0, 103.5, 110.0, 130.3, 159.4, 159.9. 
(S)-2-(5-Hydroxy-3-pyridoxyymethyl)-pyrrolidine [(S)-6a]. Obtained as a light yellow solid in 85% 
yield after chromatography on silica gel (DCM/MeOH/30%NH3 90:10:2): Rf = 0.14; m.p. = 118.26 °C; 
[α]D
25 = -5.10 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.82 (d, 1H, J = 2.2 Hz), 7.63 (d, 1H, J = 2.2 Hz), 6.83 
(t, 1H, J = 2.2 Hz), 5.85 (bs, 2H), 4.01 (dd, 1H, J = 9.1, 3.3 Hz), 3.81 (t, 1H, J = 9.1 Hz), 3.64-3.57 (m, 
1H), 3.12-2.99 (m, 2H), 2.05-1.81 (m, 3H), 1.56 (m, 1H); 13C-NMR (CDCl3): ppm 25.5, 27.9, 46.2, 
57.2, 70.8, 110.3, 125.5, 132.9, 155.9, 156.6. 
(S)-2-(2-Methoxyphenoxymethyl)pyrrolidine [(S)-7a]. Obtained as a light brown oil in 81% yield: 
[α]D
25 = +0.87 (c 1, CHCl3); 
1H NMR (CDCl3) δ 6.96-6.78 (m, 4H), 4.03-3.87 (m, 2H), 3.84 (s, 3H), 
3.56 (m, 1H), 3.18-2.92 (m, 3H), 1.96-1.68 (m, 3H), 1.62-1.51 (m, 1H); 13C-NMR (CDCl3) δ 25.3, 28.1, 
46.5, 56.1, 57.5, 72.7, 112.2, 114.3, 121.1, 121.6, 148.7, 149.9. 
(S)-2-(2-Methoxy-5-hydroxyphenoxymethyl)pyrrolidine [(S)-9a]. Obtained as a light yellow oil in 68% 
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yield after chromatography on silica gel (DCM/MeOH/30%NH3 90:10:2): Rf = 0.27; [α]D
25 = +4.9 (c 1, 
CHCl3); 
1H NMR (CDCl3) δ 6.67 (d, 1H, J = 8.6 Hz), 6.45 (d, 1H, J = 2.7 Hz), 6.35 (dd, 1H, J = 8.6, 2.7 
Hz), 3.90 (m, 2H), 3.75 (s, 3H), 3.57 (m, 3H, 2 exchange with D2O), 3.18-3.05 (m, 1H), 3.01-2.90 (m, 
1H), 2.05-1.75 (m, 3H), 1.62-1.51 (m, 1H); 13C-NMR (CDCl3) δ 25.1, 27.8, 46.2, 57.1, 57.9, 71.5, 
104.0, 108.1, 114.1 143.2, 149.1, 151.7. 
(S)-2-(2-Methoxy-3-pyridyloxyymethyl-pyrrolidine [(S)-11a]. Obtained as a light yellow oil in 75% 
yield: [α]D
25 = +5.84 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.72 (dd, 1H, J = 1.4, 4.9 Hz,), 7.06 (dd, 1H, J = 
1.4, 7.7 Hz), 6.80 (dd, 1H, J = 4.9, 7.7 Hz,), 3.99 (s, 3H), 3.98-3.84 (m, 2H), 3.62-3.50 (m, 1H), 3.04-
2.93 (m, 2H), 2.15 (bs, 1H, exchange with D2O), 1.98-1.74 (m, 3H), 1.60-1.51 (m, 1H); 
13C-NMR 
(CDCl3) δ 25.3, 28.2, 46.7, 53.7, 57.2, 72.6, 116.9, 119.3, 137.6, 143.8, 152.1. 
(S)-2-(4-Methoxy-3-pyridyloxymethyl)pyrrolidine [(S)-12a]. Obtained as a light yellow oil in 91% 
yield after chromatography on silica gel (DCM/MeOH/30%NH3 95:5:2): Rf = 0.17; [α]D
25 = +3.5 (c 1, 
CHCl3); 
1H NMR (CDCl3) δ 8.16 (d, 1H, J = 5.2 Hz), 8.15 (s, 1H), 6.78 (d, 1H, J = 5.2 Hz), 4.03 (dd, 
1H, J = 9.4, 4.9 Hz), 3.95 (dd, 1H, J = 9.4, 6.9 Hz), 3.88 (s, 3H), 3.63-3.46 (m, 1H), 3.06-2.96 (m, 2H), 
2.82 (bs, 1H, exchange with D2O), 1.99-1.77 (m, 3H), 1.63-1.54 (m, 1H); 
13C-NMR (CDCl3) δ 25.3, 
28.1, 46.6, 55.8, 57.5, 73.4, 106.9, 136.5, 144.9, 145.4, 155.9. 
(S)-N-Boc-2-(3-hydroxyphenoxymethyl)azetidine [(S)-19]. Obtained as a light brown oil in 96% yield: 
[α]D
25 = -78.8 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.25-7.06 (m, 1H), 6.47-6.39 (m, 3H), 4.52-4.45 (m, 
1H), 4.23 (dd, 1H, J = 10.2, 5.2 Hz), 4.05 (dd, 1H, J = 10.2, 2.7 Hz), 3.99-3.81 (m, 2H), 2.39-2.17 (m, 
2H), 1.26 (s, 9H). 
(R,S)-N-Boc-2-[1-(3-hydroxyphenoxy)ethyl]pyrrolidine [(R,S)-27]. Obtained as an oil in 92% yield 
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after chromatography on silica gel (toluene/EtOAc 95:5): Rf = 0.12; [α]D
25 = -101.0 (c 0.5, CH3OH); 
1H 
NMR (CDCl3) δ 7.10 (m, 1H), 6.41 (m, 3H), 4.98 (m, 0.7H), 4.64 (m, 0.3H), 3.86-3.77 (m, 1H), 3.32-
3.18 (m, 2H), 2.22-2.16 (m, 1H), 2.14-1.78 (m, 3H), 1.55-1.38 (m, 9H), 1.21 (m, 3H). 
(S,S)-N-Boc-2-[1-(3-hydroxyphenoxy)ethyl]pyrrolidine [(S,S)-27]. Obtained as an oil in 42% yield 
after chromatography on silica gel (toluene/EtOAc 95:5): Rf = 0.18; [α]D
25 = +12.2 (c 0.6, CHCl3); 
1H 
NMR (CDCl3) δ 7.08 (t, 1H, J = 8.25 Hz), 6.61-6.45 (m, 3H), 4.98-4.78 (m, 1H), 4.12-4.22 (m, 1H), 
3.53-3.38 (m, 1H), 3.36-3.08 (m, 1H), 2.03-1.79 (m, 4H), 1.50 (s, 9H), 1.19 (d, 3H, J = 6.3 Hz). 
General Procedure for Synthesis of Compounds 5, 7, 8, 10, 11, 17 and 28. The S isomers of 5, 7, 
11, 17 were obtained by treatment of (S)-19, (S)-15, (S)-22, and (S)-14, respectively, with LiAlH4 (3 
mol) in boiling THF for 2 hours. Under the same conditions, the R,S isomers of 25, 27 and 24 gave 
(R,S)-8, (R,S)-10 and (R,S)-28, respectively, and the S,S isomers of 27 and 24 gave (S,S)-10 and (S,S)-28 
respectively. By the same reaction, the S,S isomer of 8 was obtained in mixture with (R,S)-8 from the 
(R,S)/(S,S) diastereomeric mixture of 25.  
(S)-N-Methyl-2-(3-hydroxyphenoxymethyl)azetidine [(S)-5]. Obtained as a white solid solid in 63% 
yield after DCM/water extraction, adjustment of pH to 8 by formic acid, extraction with EtOAc, 
combination and concentration of the DCM and EtOAc extracts: mp 116.5 °C; [α]D
25 = +34.3 (c 1, 
CHCl3); 
1H NMR (CDCl3) δ 6.96 (t, J = 8.5 Hz, 1H), 6.38-6.41 (m, 2H), 6.23 (dd, J = 8.5, 2.2 Hz, 1H), 
3.98-3.89 (m, 2H), 3.59 (m, 2H), 3.04-2.92 (m, 1H), 2.58 (s, 3H), 2.06-2.19 (m, 2H); 13C-NMR (CDCl3) 
δ ppm 20.0, 45.6, 53.4, 66.5, 71.0, 103.9, 104.1, 109.5, 130.0, 158.2, 159.6. 
(S)-N-Methyl-2-(2-methoxyphenoxymethyl)pyrrolidine [(S)-7]. Obtained as a light yellow oil in 80% 
yield after destruction of the excess of hydride by water, filtration through Celite , concentration of the 
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filtrate, DCM/1M/NaOH extraction of the resulting residue and concentration of the organic phase: 
[α]D
25 = -42.7 (c 1, CHCl3); 
1H NMR (CDCl3) δ 6.90 (m, 4H), 4.04 (dd, 1H, J = 5.5, 9.4 Hz), 3.90 (dd, 
1H, J = 6.3, 9.4 Hz), 3.85 (s, 3H), 3.10 (m, 1H), 2.79-2.68 (m, 1H), 2.51 (s, 3H), 2.35-2.25 (m, 1H), 
2.10-1.95 (m, 1H), 1.85-1.69 (m, 3H); 13C-NMR (CDCl3) δ 23.2, 29.3, 41.9, 56.2, 57.9, 64.5, 72.6, 
112.4, 113.8, 121.3, 121.6, 148.5, 149.9. 
 (R,S)-N-Methyl-2-(1-phenoxyethyl)pyrrolidine [(R,S)-8]. Obtained as a white amorphous solid in 
60% yield after destruction of the excess of hydride by water, filtration through celite, concentration of 
the filtrate, DCM/1M HCl extraction of the resulting residue, alkalinisation of the aqueous phase by 1 M 
NH3, extraction with EtOAc and concentration of the organic phase: [α]D
25 = -72.0 (c 0.5, CH3OH); 
1H 
NMR (CDCl3) δ 7.31-7.22 (m, 2H), 6.93-6.82 (m, 3H), 4.40 (dq, 1H, J = 3.6, 6.1 Hz), 3.12 (m, 1H), 
2.48 (m, 1H), 2.43 (s, 3H), 2.30-2.18 (m, 1H), 1.94-1.70 (m, 4H), 1.28(d, 3H, J = 6.1 Hz,); 13C-NMR 
(CDCl3) δ 16.3, 23.35, 26.9, 42.4, 58.3, 69.3, 74.5,116.4, 120.8, 129.6, 158.2.  
(R,S) and (S,S)-N-Methyl-2-(1-phenoxyethyl)pyrrolidine [(R,S)-8 + (S,S)-8]. Obtained, according to 
the procedure described for (R,S)-8, as a yellow oil in 80% yield and in 1:1 diastereomeric ratio: 1H 
NMR (CDCl3) δ 7.33-7.18 (m, 2H), 6.98-6. 80 (m, 3H), 4.50-4.37 (m, 1H), 3.12 (m, 1H), 2.57 (m, 
0.5H), 2.47 (s, 2H), 2.43 (s, 1,5H), 2.31-2.18 (m, 1H), 1.92-1.72 (m, 4H), 1.28 (d, 1.5H, J = 6.3 Hz), 
1.26 (d, 1.5H, J = 6.3 Hz); 13C-NMR (CDCl3) δ 15.9, 16.3, 23.35, 23.36, 26.9, 27.3, 42.4, 42.7, 58.3, 
58.4, 68.7, 69.3, 74.5, 76.4, 116.16, 116.4, 120.6, 120.8, 129.6, 129.7, 158.1, 158.2. 
(R,S)-N-Methyl-2-[1-(3-hydroxyphenoxy)ethyl]pyrrolidine [(R,S)-10]. Obtained as a light yellow oil 
in 86% yield according to the procedure described for (R,S)-8: [α]D
25 = -47.3 (c 1, CH3OH); 
1H NMR 
(CDCl3) δ 7.05 (t, 1H, J = 8.2 Hz), 6.46-6.33 (m, 3H), 5.26 (bs, 1H, exchange with D2O), 4.47 (qd, 1H, 
J = 6.3, 3.0 Hz), 3.16 (m, 1H), 2.57 (m, 1H), 2.46 (s, 3H), 2.38 (m, 1H), 1.97-1.76 (m, 4H), 1.25 (d, 3H, 
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J = 6.3 Hz); 13C-NMR (CDCl3) δ16.6, 23.3, 26.1, 42.1, 58.1, 69.8, 73,0 104.3, 107.4, 108.4, 130.1, 
157.8, 159.0.  
(S,S)-Methyl-2-[1-(3-hydroxyphenoxy)ethyl]pyrrolidine [(S,S)-10]. Obtained as a light oil in 70% 
yield according to the procedure described for (R,S)-8: [α]D
25 = +9.4 (c 1, CH3OH); 
1H NMR (CDCl3) δ 
6.91 (t, 1H, J = 8.3, Hz), 6.28-6.20 (m, 3H), 6.01 (bs, 1H, exchange with D2O), 4.39 (quintet, 1H, J = 
6.3 Hz), 3.14 (m, 1H), 2.63-2.55 (m, 1H), 2.58 (s, 3H), 2.44-2.31 (m, 1H), 2.04-1.92 (m, 1H), 1.89-1.61 
(m, 3H), 1.21 (d, J = 6.3 Hz, 3H); 13C-NMR (CDCl3) δ 17.2, 23.2, 28.5, 43.9, 58.5, 70.1, 76.8, 104.1, 
106.9, 108.8, 129.9, 158.0, 158.8. 
(S)-N-Methyl-2-(2-methoxy-3-pyridyloxyymethyl)pyrrolidine [(S)-11]. Obtained as a light yellow oil in 
85% yield after working up as described for (R,S)-8 and chromatography of the crude product on silica 
gel (DCM/MeOH/30% NH3 95:5:2): Rf = 0.38; [α]D
25 = -52.9 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.73 
(dd, 1H, J = 1.7, 4.9 Hz), 7.06 (dd, J = 1.7, 7.7 Hz, 1H), 6.81 (dd, J = 4.9, 7.7 Hz, 1H), 3.99 (s, 3H), 
4.02-3.97 (m, 1H), 3.91-3.86 (m, 1H), 3.18-3.09 (m, 1H), 2.80-2.70 (m, 1H), 2.50 (s, 3H), 2.35-2.26 (m, 
1H), 2.17-2.01 (m, 1H), 1.85-1.67 (m, 3H); 13C-NMR (CDCl3) δ 23.3, 29.2, 42.0, 53.7, 57.9, 64.2, 72.2, 
116.9, 119.0, 137.5, 143.9, 155.1. 
 (S)-N-Methyl-2-(3-benzyloxyphenoxymethyl)pyrrolidine [(S)-17]. Obtained as a yellow oil in 83% 
yield after working up as described for (S)-7 and chromatography of the crude product on silica gel 
(DCM/MeOH/30% NH3 90:10:2): [α]D
25 = -22.7 (c 1, CHCl3); 
1H NMR (CDCl3) δ 7.52-7.38 (m, 5H), 
7.18 (m, 1H), 6.64-6.48 (m, 3H), 5.04 (s, 2H), 4.01-3.82 (m, 2H), 3.15 (m, 1H), 2.65-2.52 (m, 1H), 2.47 
(s, 3H), 2.38-2.23 (m, 1H), 2.06-1.67 (m, 4H). 
(R,S)-N-Methyl-2-(1-hydroxyethyl)pyrrolidine [(R,S)-28].Obtained as a light yellow oil in 98% yield 
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after chromatography on silica gel (DCM/MeOH/TEA 90:10:2): Rf = 0.25, 
1H NMR (CDCl3) δ 3.89 (qd, 
1H, J = 6.6, 2.2 Hz), 3.09 (m,1H), 2.33 (s, 3H), 2.27 (m, 1H), 2.13 (td, 1H, J = 8.3, 2.2 Hz), 1.86-1.79 
(m, 1H), 1.73-1.62 (m, 3H), 1.10 (d, 3H, J = 6.6 Hz). 
(S,S)-N-Methyl-2-(1-hydroxyethyl)pyrrolidine [(S,S)-28]. Obtained as a light yellow oil in 97% yield 
after chromatography on silica gel (DCM/MeOH/TEA 9:1:2%): Rf = 0.39, 
1H NMR (CDCl3) δ 3.42 
(quintet., 1H, J = 6.3 Hz), 3.07 (m, 1H), 2.48 (s, 3H), 2.44-2.34 (m, 2H), 1.95-1.83 (m, 1H), 1.82-1.68 
(m, 2H), 1.55-1.42 (m, 1H), 1.15 (d, 3H, J = 6.3 Hz). 
(S)-2-(3-Hydroxyphenoxymethyl)azetidine hydrochloride [(S)-5a·HCl]. Obtained as a light yellow 
amorphous solid in 90% yield by treatment of (S)-19 with1.25 M methanolic HCl at room temperature 
overnight: [α]D
25 = -2.9 (c 1, MeOH); 1H NMR (CD3OD) δ 7.10 (t, 1H J = 8.3 Hz), 6.47 (m, 3H), 4.85 
(m, 1H), 4.24 (d, 2H, J = 4.4 Hz), 4.11-3.98 (m, 2H), 2.57-2.67 (m, 2H); 13C-NMR (CD3OD);
 13C-NMR 
(CDCl3) δ 20.7, 43.5, 59.7, 66.4, 102.0, 105.4, 108.8, 129.9, 158.8, 159.4. 
(S)-N-Methyl-2-(5-hydroxy-3-pyridyloxymethyl)pyrrolidine [(S)-6]. Obtained as a light yellow oil 
in 92% yield by hydrogenation (H2 1 atm, Pd/C) of (S)-21 in methanol for 2 h and, after adding an 
excess of formalin, for additional 4 h and subsequent chromatography on silica gel 
(DCM/MeOH/30%NH3 90:10:2): Rf = 0.43; [α]D
25 = -30.1 (c 0.25, CHCl3); 
1H NMR (CDCl3) δ 7.81 (d, 
1H, J = 2.2 Hz), 7.74 (d, 1H, J = 2.2 Hz), 6.70 (t, 1H, J = 2.2 Hz), 4.16 (bs, 1H), 4.00-3.88 (m, 2H), 
3.16 (m, 1H), 2.78 (m, 1H), 2.52 (s, 3H), 2.33-2.42 (m,1H), 2.18-1.98 (m, 1H), 1.86-1.65 (m, 3H); 13C-
NMR (CDCl3) δ 23.3, 28.5, 42.4, 58.0, 64.8, 70.8, 110.1, 128.2, 131.3, 155.2, 156.2. 
(S)-N-Methyl-2-(2-methoxy-5-hydroxyphenoxymethyl)pyrrolidine [(S)-9]. Obtained from (S)-16 
in 80% yield as a light yellow solid under the reaction conditions described for (S)-6 and by 
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chromatography on silica gel (DCM/MeOH/30%NH3 95:5:2): Rf = 0.47; mp 88.1 °C; [α]D
25 = -38.2 (c 
1, CHCl3); 
1H NMR (CDCl3) δ 6.68 (d, 1H, J = 8.6 Hz), 6.44 (d, 1H, J = 2.7 Hz), 6.35 (dd, 1H, J = 8.6, 
2.7 Hz,), 4.05 (dd, 1H, J = 9.6, 6.1 Hz), 3.90 (dd, 1H, J = 9.6, 5.2 Hz), 3.76 (s, 3H), 3.82-3.41 (bs, 1H, 
exchange with D2O), 3.23 (m, 1H), 2.92 (m, 1H), 2.60 (s, 3H), 2.43 (m, 1H), 2.24-2.05 (m, 1H), 1.95-
1.61 (m, 3H); 13C-NMR (CDCl3) δ 22.9, 28.8, 42.0; 57.2, 57.9, 64.9, 71.6, 103.3, 107.8, 114.1, 143.3, 
149.4, 151.3. 
(S)-N-Methyl-2-(4-methoxy-3-pyridyloxymethyl)pyrrolidine [(S)-12]. Obtained from (S)-23 in 
85% yield as a light yellow oil under the reaction conditions described for (S)-6 and by chromatography 
on silica gel (DCM/MeOH/30%NH3 95:5:2): Rf = 0.30; [α]D
25 = -17.7 (c 0.8 CHCl3); 
1H NMR (CDCl3) 
δ 8.15 (m, 2H), 6.78 (d, 1H, J = 5.2 Hz), 4.04 (dd, 1H, J = 9.4, 5.5), 3.94 (dd, 1H, J = 9.4, 5.8), 3.88 (s, 
3H), 3.10 (m, 1H), 2.72 (m, 1H), 2.50 (s, 3H), 2.34-2.26 (m, 1H), 2.11-1.95 (m, 1H), 1.88-1.67 (m, 3H); 
13C-NMR (CDCl3) δ 23.2, 28.9, 41.9, 55.8, 57.9, 64.5, 73.0, 106.9, 136.2, 144.8, 145.5, 155.9. 
Biological Assays  
Binding studies. Details of the binding experiments to the nicotinic receptor subtypes have been 
published in ref. 22 for the α4β2 and α7 subtypes, and in ref. 31 for the α3β4 subtype. The Ki values 
were obtained by simultaneously fitting three independent saturation and competition binding 
experiments for each compound on each subtype. The experimental data were analyzed by means of a 
non-linear least square procedure using the LIGAND program.  
Electrophysiological experiments  
The human α3β4 and α4β2 nAChRs were expressed by transient transfection in the rat anterior pituitary 
GH4C1 cell line.38 Transient transfection was achieved by adding to each well 0.5 µg of each subunit 
cDNA, along with 2 µl of MagnetofectionTM: NeuroMag (OZ Biosciences, France). All culture media 
were purchased from Invitrogen (Italy). Whole-cell current recordings were performed 2-3 days after 
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transfection. Recordings and data analysis were performed by using borosilicate glass patch pipette (3- 
to 6-MΩ tip resistance) connected to an Axopatch 200A amplifier (Axon Instruments, Foster City, CA). 
Data were stored on a PC computer by using PCLAMP10 software (Molecular Devices). During the 
recording period, the cells were bathed in the following solution (mM): 140 NaCl, 2 CaCl2, 2.8 KCl, 2 
MgCl2, 10 Hepes/NaOH and 10 glucose; pH 7.3. The patch pipettes were filled with a solution 
containing (mM): 140 CsCl, 2 MgATP, 10 Hepes/CsOH and 5 BAPTA; pH 7.3. Whole-cell capacitance 
and patch series resistance (5-15 MΩ) were estimated from slow transient compensations. A series 
resistance compensation of 85-90% was obtained in all cases. The cells were voltage-clamped at a 
holding potential of -70 mV and continuously perfused with a gravity-driven system using independent 
external tubes for the control and agonist-containing solutions. These tubes were positioned 50-100 µm 
from the patched cell and connected to a fast exchanger system (RSC-160, BioLogic, France). Dose-
response relationships were construct by sequentially applying different concentrations of agonists, and 
normalizing the obtained current amplitudes to the value obtained by applying 1 mM µM ACh on the 
same cell. For quantitative estimations of agonist actions, dose-response relationship were fitted, when 
possible, by the equation:  
I = Imax ( [C]nH / (EC50
nH + [C]nH) ), where I is the peak current amplitude induced by the agonist at 
concentration [C], Imax is the maximum response of the cell, nH is the Hill coefficient and EC50 is the 
concentration for which a half maximum response is induced. 
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Supporting information available. 1H NMR and 13C NMR spectra and elemental analysis results for 
the final compounds 4-13, 4a-7a, 9a, 11a and 12a. 1H NMR spectra of the R,S and S,S diastereomers of 
the intermediates 24, 27 and 28 and the DSC trace of (S,S)-24. This material is available free of charge 
via the Internet at http://pubs.acs.org. 
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